Gilead told to waive remdesivir patent rights

02-04-2020

Rory O'Neill

Gilead told to waive remdesivir patent rights

Sundry Photography / Shutterstock.com

Almost 150 health and poverty activist campaigns, including Médecins Sans Frontières, have urged Gilead Sciences to waive patent and exclusivity rights for potential COVID-19 treatment remdesivir.


Gilead, COVID-19, remdesivir, Médecins Sans Frontières, Ebola, patent, Daniel O’Day, orphan drug

LSIPR